Clinical Studies of Oral Quinolone Once Daily in the Treatment of Lower Respiratory Tract Infections.

Abstract

The efficacy and safety of oral of loxacin, 400 mg once daily, for the treatment of patients with lower respiratory tract infections were studied. The most common species recovered from the sputum specimens of these patients were Haemophilus influenzae, followed by Streptococcus pneumoniae (S.pneumoniae), Staphylococcus aureus (S. aureus), Gram positive cocci unidentified, Pseudomonas aeruginosa (P. aeruginosa), Morexella catarrhalis, Streptococcus epidermidis, and another Haemophilus species in this order. All these bacteria were susceptible to of loxacin except for one strain of methicillin resistant S. aureus. A satisfactory clinical outcome was achieved in 34 of 40 patients (85%). It is concluded that of loxacin, 400 mg once daily, is useful for patients with respiratory tract infections.

Once-Daily Use of Ofloxacin for Prophylaxis in Breast Cancer Surgery

“…Once-daily use of quinolone is effective for lower respiratory [1] and urinary [2,3] tract infections. After a single oral dose of ofloxacin, the concentration at t max (2.17 h) is 2.23 Ìg/ml, high enough for single doses to be effective [6].…”

“…Wound infection is seldom life-threatening, but it may delay rehabilitation. Promising results with the once-daily use of ofloxacin have been reported [1][2][3]. If the once-daily use of ofloxacin is as useful as the higher dose, it would be preferable for postoperative prophylaxis for financial reasons and increased patient compliance.…”